Shopping Cart
- Remove All
Your shopping cart is currently empty
Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $455 | In Stock | |
| 5 mg | $1,360 | In Stock | |
| 10 mg | $1,830 | 2-4 weeks | |
| 25 mg | $2,730 | 2-4 weeks |
| Description | Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer. |
| In vivo | Sacituzumab govitecan administered at a dose of 17.5 mg/kg twice weekly for four consecutive weeks showed significant antitumor effects in mice bearing human gastric cancer xenograft tumors. [1] |
| Synonyms | IMMU-132 |
| Molecular Weight | 160 KDa (Approximately) |
| Cas No. | 1491917-83-9 |
| Storage | store at low temperature | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O: 20 mg/mL, Sonication is recommended. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.